196 filings
Page 8 of 10
6-K
xq79w6go9c1l0ryladk
5 Nov 21
Evaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering
8:30am
EFFECT
vo4zto42g9j2vv qdv6k
5 Nov 21
Notice of effectiveness
12:15am
F-1MEF
969k 228r
4 Nov 21
Registration statement to add securities to prior F-1 registration
8:19pm
F-1/A
n8m595jzr8 a5v4
3 Nov 21
Registration statement (foreign) (amended)
7:50am
CORRESP
at39otdvu arc3
3 Nov 21
Correspondence with SEC
12:00am
CORRESP
dyootg tvaq9s
3 Nov 21
Correspondence with SEC
12:00am
CORRESP
l4w1n
29 Oct 21
Correspondence with SEC
12:00am
CORRESP
11pmj d22lidnk
29 Oct 21
Correspondence with SEC
12:00am
6-K
hbdm27x2zy 6h
27 Oct 21
Evaxion Biotech Announces Filing of Registration Statement in the U.S for Proposed Follow-on Public Offering to Raise Additional Capital
4:29pm
6-K
uqw jjvlty
26 Oct 21
Current report (foreign)
8:14am
F-1
x6qmjkw5fes 17m1t5l
26 Oct 21
Registration statement (foreign)
7:02am
6-K
7bi1h36gy9l7
25 Oct 21
Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA® (pembrolizumab) in Patients with Melanoma
6:00am
6-K
fa7c2c zcadff6ii8
18 Oct 21
Current report (foreign)
4:30pm
6-K
co1z2gcyr1aekgut
13 Aug 21
Current report (foreign)
4:06pm
6-K
trzi44l
12 Aug 21
Evaxion Biotech Announces Q2 2021 Financial Results and Provides Business Update
9:09am
6-K
df5z5ph4 b65
8 Jul 21
Evaxion Biotech Reports Data from Phase 1/2a Trials of EVX-01 and EVX-02
7:00am
UPLOAD
0q4 ghix6r
29 Jun 21
Letter from SEC
12:00am
6-K
yur4tet g8kpoq5j39
25 Jun 21
Evaxion Develops Method to Enhance AI Drug Development with Deep Probabilistic Programming
4:30pm
DRS
k7cnq6jot5xyml4zp
25 Jun 21
Draft registration statement
12:00am
DRSLTR
vot 9v3jp
25 Jun 21
Correspondence regarding draft registration statement
12:00am